Expression of Drosophila epidermal growth factor receptor homologue in mitotic cell populations

Development ◽  
1987 ◽  
Vol 100 (2) ◽  
pp. 201-210 ◽  
Author(s):  
K.L. Kammermeyer ◽  
S.C. Wadsworth

Expression of the Drosophila homologue (DER) of the human epidermal growth factor (EGF) receptor has been studied during development by RNA blot hybridizations and in situ hybridizations. One of the hypothetical functions of the protein encoded by this gene is mitotic signal transduction and, therefore, we have searched for evidence of its expression in mitotic cell populations. Increased DER transcript levels were detected in virtually all cells in cellular blastoderm embryos, indicative of the onset of transcription of the gene at this stage of development. These transcripts persist at least until the formation of the ventral furrow at the beginning of gastrulation. Expression of DER has been investigated in populations of nondividing cells, imaginal cells and nervous tissue in third instar larvae. By RNA blot hybridizations, we have shown that imaginal discs contain the bulk of the DER transcripts present in the whole third instar larvae. This result has been confirmed by in situ hybridizations. All imaginal discs, representing dividing cells, contain DER transcripts while salivary glands, representing nondividing cells, do not. Within the central nervous system, hybridization of the DER probe is confined to small clusters of cells in the brain cortex. During oogenesis, cell division programs are highly ordered temporally and spatially. Follicle cells express high levels of DER RNA during their mitotic phase of growth but lose these transcripts as they cease division. Nurse cells also express DER transcripts at lower levels even though they are not dividing. However, nurse cell transcripts represent stored maternal RNA species destined for use during preblastoderm embryonic development. These results indicate that the DER gene is expressed in mitotic cell populations during several stages of development and is not expressed in certain populations of nonmitotic cells.

2000 ◽  
Vol 278 (5) ◽  
pp. C982-C988 ◽  
Author(s):  
Roni Levy ◽  
Steven D. Smith ◽  
Kala Chandler ◽  
Yoel Sadovsky ◽  
D. Michael Nelson

Preeclampsia and fetal growth restriction are associated with placental hypoperfusion and villous hypoxia. The villous response to this environment includes diminished trophoblast differentiation and enhanced apoptosis. We tested the hypothesis that hypoxia induces apoptosis in cultured trophoblasts, and that epidermal growth factor (EGF), an enhancer of trophoblast differentiation, diminishes hypoxia-induced apoptosis. Trophoblasts isolated from placentas of term-uncomplicated human pregnancies were cultured up to 72 h in standard ([Formula: see text]= 120 mmHg) or hypoxic ([Formula: see text] < 15 mmHg) conditions. Exposure to hypoxia for 24 h markedly enhanced trophoblast apoptosis as determined by DNA laddering, internucleosomal in situ DNA fragmentation, and histomorphology, as well as by the reversibility of the apoptotic process with a caspase inhibitor. Apoptosis was accompanied by increased expression of p53 and Bax and decreased expression of Bcl-2. Addition of EGF to cultured trophoblasts or exposure of more differentiated trophoblasts to hypoxia significantly lowered the level of apoptosis. We conclude that hypoxia enhances apoptosis in cultured trophoblasts by a mechanism that involves an increase in p53 and Bax expression. EGF and enhancement of cell differentiation protect against hypoxic-induced apoptosis.


1987 ◽  
Vol 138 (5) ◽  
pp. 1329-1335 ◽  
Author(s):  
Edward M. Messing ◽  
Patricia Hanson ◽  
Peter Ulrich ◽  
Edrogen Erturk

2014 ◽  
Vol 80 (10) ◽  
pp. 936-939 ◽  
Author(s):  
Anna Weiss ◽  
Vivi Tran ◽  
Jennifer Baker ◽  
Hasteh Farnaz ◽  
Anne M. Wallace ◽  
...  

Patients with human epidermal growth factor receptor 2 (HER2neu)-positive breast invasive cancer are known to have larger, more aggressive tumors. Little research exists on the relationship between HER2neu status and extent of ductal carcinoma in situ (DCIS). A retrospective review of a single-institution database was performed for patients with DCIS between the years 2002 and 2011. A single blinded breast radiologist reviewed preoperative imaging. Pathology was reviewed for extent of DCIS. Primary outcome was mastectomy. Multivariate logistic regression was used to determine adjusted mastectomy risk. There were 166 cases, 34 HER2neu-positive. HER2neu receptor-positive patients had larger lesions on imaging: 4.0 versus 2.7 cm, by 2.9 versus 1.5 cm ( P = 0.0499 and 0.0182). HER2neu-positive patients with DCIS were more likely than HER2neu-negative to undergo mastectomy than lumpectomy (53 vs 28%, P = 0.006). Pathology revealed a trend toward larger lesions in HER2neu-positive patients (2.96 vs 2.22 cm, nonsignificant). Patients with HER2neu-positive disease were three times more likely to undergo mastectomy (odds ratio, 2.9; 95% confidence interval, 1.23 to 6.78). Patients with HER2neu-positive DCIS had greater extent of disease by imaging and were more likely to undergo mastectomy than HER2neu-negative. These findings will help surgeons counsel patients on surgical treatment.


Sign in / Sign up

Export Citation Format

Share Document